This study investigated the effect of co‐treatment using erythropoietin‐derived helix B surface peptide (HBSP) and caspase‐3 small interfering RNA (CASP3siRNA) on preventing fibrosis post AKI in order to achieve better efficacy by different action mechanisms. This evidence concerns the gene EPO and acute kidney injury.